m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02491)
Name
Ro-27-3225
Status
Preclinical
Structure
3D MOL
2D MOL
Formula
C41H54N10O6
InChI
1S/C41H54N10O6/c1-3-12-36(53)47-32(21-27-15-7-8-16-27)38(55)49-33(22-26-13-5-4-6-14-26)39(56)48-31(19-11-20-45-41(43)44)37(54)50-34(40(57)51(2)25-35(42)52)23-28-24-46-30-18-10-9-17-29(28)30/h4-10,13-15,17-18,31-34H,3,11-12,16,19-25H2,1-2H3,(H2,42,52)(H,47,53)(H,48,56)(H,49,55)(H,50,54)(H4,43,44,45)/t31-,32-,33?,34?/m0/s1
InChIKey
IRCWGIYPMAYZQR-URRMOVRVSA-N
PubChem CID
56603736
TTD Drug ID
D0N0IQ
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Melanocortin receptor 4 (MC4R)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Melanocortin receptor 4 (MC4R) is a therapeutic target for Ro-27-3225. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Ro-27-3225 through regulating the expression of Melanocortin receptor 4 (MC4R). [1], [2]
References
Ref 1 Demethyltransferase FTO alpha-ketoglutarate dependent dioxygenase (FTO) regulates the proliferation, migration, invasion and tumor growth of prostate cancer by modulating the expression of melanocortin 4 receptor (MC4R). Bioengineered. 2022 Mar;13(3):5598-5612. doi: 10.1080/21655979.2021.2001936.
Ref 2 The protective effects of the melanocortin receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in mice. Neuropeptides. 2014 Feb;48(1):47-51. doi: 10.1016/j.npep.2013.11.001. Epub 2013 Nov 15.